Sensorion to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

MONTPELLIER, France–(BUSINESS WIRE)– Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a biotech company
specializing in the treatment of inner ear diseases, today announced
that Laurent Nguyen, Chief Executive Officer, is scheduled to present at
the 18^th Annual Rodman & Renshaw Global Investment
Conference, being held on September 11-13, 2016 at The Lotte New York
Palace Hotel in New York City.

Dr. Nguyen will provide an overview of the company’s upcoming clinical
and operational plans during a live presentation. Details of the
presentation are as follows:

Date: Monday, September 12, 2016
Time: 11:15 AM EST
Room:
Louis (4^th Floor)

Investors attending the conference who would like to schedule a
one-on-one meeting with Sensorion’s management may do so by contacting
their Rodman & Renshaw representatives, or Chris Nardo at The Ruth Group
at cnardo@theruthgroup.com.

The presentation will also be webcast live. To access the webcast,
please visit the Company’s website at www.sensorion.com.
The webcast replay will remain available for 90 days following the live
presentation.

About Sensorion

Spun off from Inserm (the French institute of health and medical
research) in 2009, Sensorion is a biotech company that specializes in
the treatment of pathologies of the inner ear such as acute vertigo,
tinnitus and hearing loss. The Company has substantial pharmaceutical
R&D experience and a comprehensive technological platform for developing
easy-to-take (notably orally) first-in-class drug candidates for
treating hearing loss and the symptoms of vertigo or tinnitus, for
preventing complications associated with progressive lesions in the
inner ear and for preventing the toxicity of chemotherapy in the inner
ear. Based in Montpellier, southern France, Sensorion receives financial
support from Bpifrance, through the InnoBio fund, and Inserm Transfert
Initiative.

For more information: www.sensorion-pharma.com

Name: SENSORION
ISIN code: FR0012596468
Ticker: ALSEN

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901006018/en/